Continued here: Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results
Continued here: Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results
See original here: Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
See the rest here: TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business Update
See more here: Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell...
View post: Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023
Read the rest here: Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office
Read more here: Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
Read more: Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive Ichthyosis
Follow this link: Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all...
Recent Comments